Agennix AG Schedules Conference Call on May 6, 2010 to Discuss First Quarter 2010 Financial Results

MARTINSRIED/MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - April 30, 2010) - Agennix AG (FRANKFURT: AGX) today announced that the Company will hold a conference call to discuss financial results for the first quarter of 2010 and to provide a business update. The results will be published on Thursday, May 6, 2010 in advance of the conference call.

The conference call, which will be conducted in English, will be held on Thursday, May 6, 2010 at
9 AM ET/ 3 PM CET.

A live webcast will be available on the Agennix Web site at www.agennix.com. A replay will be available via the Web site following the live event.

Dial-in numbers for the call are as follows:

Participants from Europe: 0049 (0)69 667775756 0044 (0)20 3003 2666 Participants from the U.S.: 1-646-843-4608 

Please dial in 10 minutes before the beginning of the meeting.

About Agennix
Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients. The Company’s most advanced program is talactoferrin, an oral targeted therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase 2 studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix’s registered seat is in Heidelberg, Germany. The Company has three sites of operation: Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.